Prognosis and Mechanisms of Death in ARDS

Current Mortality Rates

The American Thoracic Society notes that ARDS mortality has improved significantly over time, declining from 60-70% in early reports to approximately 40% in more recent data, though severe ARDS still carries 46-60% in-hospital mortality, with death occurring primarily from multi-organ failure and sepsis rather than isolated respiratory failure 1, 2
Overall mortality for ARDS is approximately 40%, representing substantial improvement from historical rates of 60-70% 1, 2, 3

The Society of Critical Care Medicine recommends that the number of organ failures be considered the single most important prognostic indicator for ARDS patients requiring intensive care 1, 2, 3
Death more commonly results from sequelae of sepsis and multiple organ dysfunction syndrome rather than from respiratory failure itself, as noted by the European Society of Intensive Care Medicine 3, 4
Patients developing progressive fibrosis have significantly poorer outcomes, as vascular bed obliteration contributes to increased dead-space ventilation and right ventricular strain, according to the American College of Chest Physicians 3, 4

The American Thoracic Society states that liver failure in association with ARDS carries a particularly poor prognosis 1, 2, 3
Right ventricular failure can be precipitated by lung collapse and increased afterload, particularly in pneumonia-related ARDS, as reported by the European Respiratory Society 5

The American College of Chest Physicians notes that injurious modes of mechanical ventilation can produce cytokine release and end-organ damage, directly contributing to mortality 2, 3
High driving pressures (≥18 cmH₂O) increase risk of clinical deterioration, according to the Society of Critical Care Medicine 5

The European Society of Intensive Care Medicine recommends that development of pulmonary fibrosis during ARDS course be considered a poor prognostic indicator 1, 2, 3
Inability to concentrate protein in edema fluid during first 12 hours (indicating impaired epithelial barrier integrity) is a poor prognostic indicator, as noted by the American Thoracic Society 1, 6, 4
Lack of improvement in oxygenation parameters following initial treatment is a poor prognostic indicator, according to the American College of Chest Physicians 1, 6

The American College of Chest Physicians states that intact epithelial barrier function with ability to actively transport fluid out of alveoli is a favorable prognostic indicator 1, 6, 4
Rapid resolution of ARDS (within 10-14 days) with parallel decreases in minute ventilation and dead-space ventilation is a favorable prognostic indicator, as reported by the European Respiratory Society 3
Improvement in oxygenation parameters within first 48 hours is a favorable prognostic indicator, according to the Society of Critical Care Medicine 5

The American Thoracic Society notes that the long-term functional outlook for ARDS survivors is generally good 1, 6, 7
Most improvement in pulmonary function and perceived health occurs within the first 3 months following ARDS, as reported by the European Society of Intensive Care Medicine 1, 6, 7
Long-term pulmonary function abnormalities are more common if lung impairment persists beyond a few days after ARDS onset, according to the American College of Chest Physicians 1, 6

The Society of Critical Care Medicine recommends that death not be attributed solely to respiratory failure - investigate and aggressively manage evolving organ dysfunction, particularly hepatic and cardiovascular 1
Monitor for fibroproliferative changes - patients developing significant fibrosis require different ventilatory strategies as their dead-space ventilation remains elevated despite improving oxygenation, as noted by the European Respiratory Society 3, 4
Recognize that ventilator settings themselves can kill - excessive plateau pressures and driving pressures directly contribute to mortality through cytokine release and multi-organ injury, according to the American College of Chest Physicians 2
Early epithelial barrier assessment matters - inability to concentrate edema fluid protein in the first 12 hours predicts poor outcome and should trigger more aggressive supportive measures, as reported by the American Thoracic Society 1, 6, 4